Why the study?
Can proteomic profiling identify biomarkers for the diagnosis, molecular classification, and risk stratification of soft-tissue sarcomas?
Population
80 soft-tissue sarcoma samples with seven different histological backgrounds
Authors
Loading...
May aid sarcoma subtyping and risk stratification; leaves open prospective validation before clinical use.
Can proteomic profiling identify biomarkers for the diagnosis, molecular classification, and risk stratification of soft-tissue sarcomas?
Proteomic profiling can classify soft-tissue sarcomas and identify high-risk grade III patients who may benefit from adjuvant therapy.
Suehara et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: